EntryPoint Capital’s Xenon Pharmaceuticals XENE Stock Holding History

EntryPoint Capital's XENE Position: Q2 2026 in Review

EntryPoint Capital increased its Xenon Pharmaceuticals (XENE) stake by 49% in Q2 2026, buying an estimated $241K and bringing the position to 13,177 shares worth $795K. The position accounts for 0.19% of the portfolio, ranked #142.

EntryPoint Capital first reported a position in XENE in Q1 2024 and has held it in 7 quarters since. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

• EntryPoint Capital held 13,177 shares of Xenon Pharmaceuticals worth $795K as of Q2 2026.
• EntryPoint Capital bought 4,345 Xenon Pharmaceuticals shares in Q2 2026, an estimated $241K.
• Xenon Pharmaceuticals made up 0.19% of EntryPoint Capital's portfolio in Q2 2026, its #142 holding.
• EntryPoint Capital first reported a position in Xenon Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
• 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.